Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736302 · ClinicalTrials.gov registry record
Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water
A clinical trial of Movement Disorders and Energy Metabolism, sponsored by University of Wisconsin, Milwaukee.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT05736302: Recruiting study of Movement Disorders and Energy Metabolism, sponsored by University of Wisconsin, Milwaukee.
NCT05736302 is a study of Movement Disorders and Energy Metabolism that is actively recruiting participants, run by University of Wisconsin, Milwaukee. The registered enrollment target is 125 participants, below the 1,063-participant average among 26 other Movement Disorders trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736302, a study of Movement Disorders and Energy Metabolism, is actively recruiting participants, sponsored by University of Wisconsin, Milwaukee.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.
Primary Outcome
Accelerometer estimations will be derived by different algorithms available in the literature, as well as from a newly developed algorithm that distinguishes between those with and without movement limitations. Accelerometer estimations of TDEE will be compared to those values obtained by the criterion doubly-labeled water technique.
Conditions Studied
Interventions
- OTHER Doubly-Labeled Water
Study Locations (1)
Wisconsin
- University of Wisconsin-Milwaukee - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2026-12-31 |
What NCT05736302 shows while recruiting
NCT05736302 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 1,063-participant average among 26 other Movement Disorders trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Movement Disorders appearing as the primary indexed condition, and to 1 intervention - of which Doubly-Labeled Water is the first listed.
NCT05736302 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05736302 about?
NCT05736302 is a clinical study titled "Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water". The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.
What is the current status of trial NCT05736302?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2023-03-14. Estimated completion is 2026-12-31.
What conditions does trial NCT05736302 study?
This clinical trial studies the following conditions: Movement Disorders, Energy Metabolism.
What interventions are being tested in trial NCT05736302?
The interventions under investigation include: Doubly-Labeled Water (OTHER).
Who is sponsoring clinical trial NCT05736302?
This trial is sponsored by University of Wisconsin, Milwaukee, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736302 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Movement Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05736302's enrollment target sits among peer trials
125 11th of 26 higher than 16 of 26 other Movement Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Movement Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders
RECRUITING · NA
-
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
RECRUITING
-
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
RECRUITING
-
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
RECRUITING
-
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI